Menu
A phase II, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet.
The CEC-013/CEL study investigates the efficacy and tolerability of a 15-week treatment with placebo or ZED1227 TID up to a total dose of 75 mg/day, in subjects with treated celiac disease still experiencing symptoms.
You may be eligible for the study if you meet the following criteria.
If eligible for the study, your participation is expected to last approximately 19 weeks.
Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?
Clinical trials are important because they serve as the foundation for most medical advances.
